9.52
Schlusskurs vom Vortag:
$9.57
Offen:
$9.72
24-Stunden-Volumen:
1.44M
Relative Volume:
0.55
Marktkapitalisierung:
$1.68B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-294.51M
KGV:
-2.6742
EPS:
-3.56
Netto-Cashflow:
$-244.42M
1W Leistung:
-6.30%
1M Leistung:
-20.40%
6M Leistung:
-59.59%
1J Leistung:
-73.02%
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DYN
Dyne Therapeutics Inc
|
9.52 | 1.68B | 0 | -294.51M | -244.42M | -3.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-11 | Fortgesetzt | Raymond James | Outperform |
2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
2023-01-26 | Eingeleitet | Guggenheim | Buy |
2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
2022-07-12 | Eingeleitet | Raymond James | Outperform |
2020-10-12 | Eingeleitet | JP Morgan | Overweight |
2020-10-12 | Eingeleitet | Jefferies | Buy |
2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (DYN) Receives Continued Buy Rating from Guggenheim | DYN Stock News - GuruFocus
Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN) - Seeking Alpha
Dyne Therapeutics (DYN): Baird Lowers Price Target to $32 | DYN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent
Dyne at ‘attractive entry point’ following pullback, says Chardan - Yahoo Finance
Dyne Therapeutics (DYN) Price Target Reduced by Baird | DYN Stoc - GuruFocus
H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock - Investing.com
Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback - The Pharma Letter
Dyne’s DM1 treatment receives FDA breakthrough designation By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revi - GuruFocus
Dyne Therapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – DYN - Business Wire
Dyne Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Dyne Therapeutics (DYN) Boosted by DYNE-101 Program Updates | DY - GuruFocus
Dyne Therapeutics (DYN) Rating and Price Target Maintained by Ch - GuruFocus
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Benzinga
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | D - GuruFocus
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathw - GuruFocus
Transcript : Dyne Therapeutics, Inc.Special Call - MarketScreener
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathway Update | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Faces Setback with DYNE-101 Approval Del - GuruFocus
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Shares Drop Amid Clinical Trial Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | DYN Stock News - GuruFocus
Dyne stock on revised plan for clinical program (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics (DYN) Gains FDA Breakthrough Therapy Designati - GuruFocus
Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy - MarketScreener
Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 - Investing.com Nigeria
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Granted Breakthrough Therapy Designation - TipRanks
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - The Manila Times
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
FDA Breakthrough: Dyne's DM1 Drug Shows 20% Muscle Strength Gain in Latest Trial Data - Stock Titan
Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire
Dyne Therapeutics To Host Investor Conference Call And Webcast - marketscreener.com
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET | DYN Stock News - GuruFocus
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewswire
Dyne Therapeutics to Reveal Crucial Data on DYNE-101 DM1 Treatment: Key Clinical Updates Coming Tomorrow - Stock Titan
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James - Defense World
Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus
Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada
Dyne Therapeutics officer sells shares worth $1,949 - Investing.com
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com
Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):